Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD40L-augmented TILs |
| Synonyms | |
| Therapy Description |
CD40L-augmented TILs are autologous tumor infiltrating lymphocytes that have been activated with the CD40 ligand (CD40L; CD40LG), which potentially increase tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD40L-augmented TILs | CD40L-augmented TILs are autologous tumor infiltrating lymphocytes that have been activated with the CD40 ligand (CD40L; CD40LG), which potentially increase tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06961357 | Phase Ib/II | Interleukin-12 CD40L-augmented TILs Cyclophosphamide + Fludarabine | Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Recruiting | USA | 0 |
| NCT05681780 | Phase Ib/II | Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs | Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | Active, not recruiting | USA | 0 |